Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant

被引：127

作者：

Lyke, Kirsten E. ^{[1
]}

Atmar, Robert L. ^{[2
]}

Islas, Clara Dominguez ^{[3
]}

Posavad, Christine M. ^{[3
,4
]}

Szydlo, Daniel ^{[5
]}

Chourdhury, Rahul Paul ^{[5
]}

Deming, Meagan E. ^{[1
]}

Eaton, Amanda ^{[6
]}

Jackson, Lisa A. ^{[7
]}

Branche, Angela R. ^{[8
]}

Sahly, Hana M. El ^{[2
]}

Rostad, Christina A. ^{[9
]}

Martin, Judith M. ^{[10
]}

Johnston, Christine ^{[3
,4
,11
]}

Rupp, Richard E. ^{[12
]}

Mulligan, Mark J. ^{[13
]}

Brady, Rebecca C. ^{[14
]}

Frenck, Robert W., Jr. ^{[14
]}

Backer, Martin ^{[15
]}

Kottkamp, Angelica C. ^{[13
]}

Babu, Tara M. ^{[11
]}

Rajakumar, Kumaravel ^{[10
]}

Edupuganti, Srilatha ^{[16
,17
]}

Dobrzynski, David ^{[8
]}

Coler, Rhea N. ^{[18
,19
]}

Archer, Janet I. ^{[20
]}

Crandon, Sonja ^{[21
]}

Zemanek, Jillian A. ^{[5
]}

Brown, Elizabeth R. ^{[3
]}

Neuzil, Kathleen M. ^{[1
]}

Stephens, David S. ^{[16
]}

Post, Diane J. ^{[21
]}

Nayak, Seema U. ^{[21
]}

Suthar, Mehul S. ^{[22
]}

Roberts, Paul C. ^{[21
]}

Beigel, John H. ^{[21
]}

Montefiori, David C. ^{[23
]}

DMID Std Grp

机构：

[1] Univ Maryland Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA

[2] Baylor Coll Med, Dept Med & Mol Virol & Microbiol, Houston, TX 77030 USA

[3] Univ Washington, Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA USA

[4] Univ Washington, Fred Hutchinson Canc Res Ctr, Dept Lab Med & Pathol, Seattle, WA USA

[5] Univ Washington, Stat Ctr HIV AIDS Res & Prevent SCHARP, Fred Hutchinson Canc Res Ctr, Seattle, WA USA

[6] Duke Univ Med Ctr, Dept Surg, Durham, NC USA

[7] Kaiser Permanente Washington Hlth Res Inst, Seattle, WA USA

[8] Univ Rochester, Dept Med, Div Infect Dis, Rochester, NY USA

[9] Emory Univ Sch Med & Childrens Healthcare Atlanta, Ctr Childhood Infect & Vaccines, Dept Pediat, Atlanta, GA USA

[10] Univ Pittsburgh Sch Med, Dept Pediat, Pittsburgh, PA USA

[11] Univ Washington, Dept Med, Seattle, WA USA

[12] Univ Texas Med Branch, Sealy Inst Vaccine Sci, Galveston, TX USA

[13] NYU Langone Vaccine Ctr, NYU Grossman Sch Med, Dept Med, Div Infect Dis & Immunol, New York, NY USA

[14] Univ Cincinnati Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Infect Dis, Cincinnati, OH USA

[15] NYU Langone Hosp, Mineola, NY USA

[16] Emory Univ Sch Med, Dept Med, Atlanta, GA USA

[17] Hope Clin Emory Vaccine Ctr, Atlanta, GA USA

[18] Univ Washington Sch Med, Seattle Childrens Res Inst, Seattle, WA USA

[19] Univ Washington Sch Med, Dept Pediat, Seattle, WA USA

[20] FHI360, Durham, NC 27701 USA

[21] Natl Inst Allergy & Infect Dis, NIH, Div Microbiol & Infect Dis, Bethesda, MD USA

[22] Emory Univ, Atlanta, GA USA

[23] Duke Univ Med Ctr, Duke Human Vaccine Inst, Durham, NC 27710 USA

来源：

CELL REPORTS MEDICINE | 2022年 / 3卷 / 07期

基金：

美国国家卫生研究院;

关键词：

BA.2.12.1; BA.4/BA.5; booster; COVID-19; mRNA vaccine; neutralizing antibody; Omicron variant; recombinant adenovirus vaccine; SARS-CoV-2; sublineage;

D O I：

10.1016/j.xcrm.2022.100679

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibits reduced susceptibility to vaccine-induced neutralizing antibodies, requiring a boost to generate protective immunity. We assess the magnitude and short-term durability of neutralizing antibodies after homologous and heterologous boosting with mRNA and Ad26.COV2.S vaccines. All prime-boost combinations substantially increase the neutralization titers to Omicron, although the boosted titers decline rapidly within 2 months from the peak response compared with boosted titers against the prototypic D614G variant. Boosted Omicron neutralization titers are substantially higher for homologous mRNA vaccine boosting, and for heterologous mRNA and Ad26.COV2.S vaccine boosting, compared with homologous Ad26.COV2.S boosting. Homologous mRNA vaccine boosting generates nearly equivalent neutralizing activity against Omicron sublineages BA.1, BA.2, and BA.3 but modestly reduced neutralizing activity against BA.2.12.1 and BA.4/BA.5 compared with BA.1. These results have implications for boosting requirements to protect against Omicron and future variants of SARS-CoV-2.

引用

页数：13

共 50 条

[41] Hyperimmunized Chickens Produce Neutralizing Antibodies against SARS-CoV-2
Aston, Emily J.
Wallach, Michael G.
Narayanan, Aarthi
Egana-Labrin, Sofia
Gallardo, Rodrigo A.
VIRUSES-BASEL, 2022, 14 (07):
[42] Two SARS-CoV-2 serology assays detect antibodies in the sera of individuals diagnosed with SARS-CoV-2 Omicron variant
Conklin, Justin
Arroyo, Jennifer
Kumar, Rajnish
Patibandla, Sai
CLINICAL BIOCHEMISTRY, 2022, 103 : 35 - 36
[43] Monoclonal neutralizing antibodies against SARS-COV-2 S protein
Cheng, Lin-Dong
Li, Ping
Lin, Yan-Chen
Hu, Hui-Xiu
Zhang, Ying
Li, Hou-Feng
Huang, Jing
Tan, Li
Ma, Ning
Xia, Deng-Yun
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2024, 16 (02): : 681 - 689
[44] A neutralizing bispecific single-chain antibody against SARS-CoV-2 Omicron variant produced based on CR3022
Yu, Kaikai
Liu, Bin
Yu, Haotian
Sun, Chengbiao
Wang, Xuefeng
Li, Guorui
Dong, Mingxin
Wang, Yan
Zhang, Jianxu
Xu, Na
Liu, Wensen
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2023, 13
[45] Efficacy of the neutralizing antibodies after the booster dose on SARS-CoV-2 Omicron variant and a two-year longitudinal antibody study on Wild Type convalescents
Zheng, Yufen
Jin, Minya
Tung, Tao-Hsin
Chen, Shiyong
Bi, Xiaojie
Zhou, Kai
Chen, Mengyuan
Wang, Donglian
Li, Jun
Shen, Bo
Ying, Lingjun
INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 119
[46] Broad-spectrum humanized monoclonal neutralizing antibody against SARS-CoV-2 variants, including the Omicron variant
Wen, Kun
Cai, Jian-Piao
Fan, Xiaodi
Zhang, Xiaojuan
Luo, Cuiting
Tang, Kai-Ming
Shuai, Huiping
Chen, Lin-Lei
Zhang, Ricky Ruiqi
Situ, Jianwen
Tsoi, Hoi-Wah
Wang, Kun
Chan, Jasper Fuk-Woo
Yuan, Shuofeng
Yuen, Kwok-Yung
Zhou, Hongwei
To, Kelvin Kai-Wang
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2023, 13
[47] Neutralizing antibodies for SARS-CoV-2 infection
Berenguer, Juan
REVISTA ESPANOLA DE QUIMIOTERAPIA, 2022, 35 : 16 - 19
[48] A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain
Niu, Ling
Wittrock, Kathryn N.
Clabaugh, Gage C.
Srivastava, Vikram
Cho, Michael W.
FRONTIERS IN IMMUNOLOGY, 2021, 12
[49] SARS-CoV-2 Neutralizing Antibodies in Mexican Population: A Five Vaccine Comparison
Alcorta-Nunez, Fernando
Perez-Ibave, Diana Cristina
Burciaga-Flores, Carlos Horacio
Garza, Miguel Angel
Gonzalez-Escamilla, Moises
Rodriguez-Nino, Patricia
Gonzalez-Guerrero, Juan Francisco
Alcorta-Garza, Adelina
Vidal-Gutierrez, Oscar
Ramirez-Correa, Genaro A.
Garza-Rodriguez, Maria Lourdes
DIAGNOSTICS, 2023, 13 (06)
[50] Evaluation of Binding and Neutralizing Antibodies for Inactivated SARS-CoV-2 Vaccine Immunization
Zhao, Heng
Jiang, Guorun
Li, Cong
Che, Yanchun
Long, Runxiang
Pu, Jing
Zhang, Ying
Li, Dandan
Liao, Yun
Yu, Li
Zhao, Yong
Yuan, Mei
Li, Yadong
Fan, Shengtao
Liu, Longding
Li, Qihan
DISEASES, 2024, 12 (04)

← 1 2 3 4 5 →